These advancements are tailored to attack specific cancer cells based on genetic markers, such as mutations in the epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and c-ros oncogene 1 (ROS1) genes. This evidence concerns the gene EGFR and cancer.